The Vaccine Research Center at the National Institutes of Health conducts research that facilitates the development of effective vaccines. Towards this end, our goal has been to develop vaccine and passive immunotherapies, such as monoclonal antibodies, that can be used as both preventative treatments and acute therapies. This project enables the production of vaccine candidates, monoclonal antibodies and proteins used in assays to evaluate the quality of the vaccinations and antibodies being evaluated.

The Biodefense Research Section of the Vaccine Research Center at the National Institutes of Health develops vaccines and monoclonal antibody therapies for the treatment of biodefense related pathogens such as Ebola virus, Sudan virus, Bundibugyo virus, Marburg virus and Lassa Fever virus. These efforts require the synthesis and purification of DNA plasmid reagents and for the development and testing of therapeutic antibody and vaccine candidates. The services being purchased will provide the materials needed for the quarterly Federal Drug Administration's (FDA) testing results, which are required to comply with the current vaccine trial approval.

The requested services for synthesis of DNA coupled with protein production/purification. The sequence verifies and deliver the final DNA after additional quality controls to VRC. The service being provides custom DNA synthesis and vector purification. Changing vendors would lead to variations in final product that would lead to the loss of integrity of our data.
The Place of performance is 9000 Rockville Pike, Bethesda, MD 20892.

The statutory authority for this sole source requirement is 41 U.S.C.1901 (e) (2) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR QUOTES. All responsible sources that could provide comparable services may submit a capability statement that will be considered by email (subject line to reference NOI-NIAID-1977950) to Rita Davis at [email protected] by 1:00 pm eastern standard time, July 15, 2019. All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.